Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial
Audrey Winter(Methodology and Quality of Life Unit in Oncology), Célia Touraine(Université de Montpellier), Benjamin Cuer(Université de Montpellier), Caroline Mollévi(Inserm), Béata Juzyna(UniCancer Group), Sophie Gourgou(Université de Montpellier), Thierry Conroy(Inserm)
Cited by 4
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k